Answers are grounded in this paper and cite their sources.
Purpose: To evaluate real-world outcomes in subjects with pre-existing neovascular age-related macular degeneration (AMD) undergoing intravitreal avacincaptad pegol (IVA) treatment for geographic atrophy (GA). Methods: This study was undertaken as a retrospective, case-controlled assessment of patients undergoing IVA treatment for GA from 2 community-based retina practices. Patients were separated into 1) a Study Group consisting of subjects with pre-existing neovascular AMD prior to initiation of IVA for GA, and 2) a Control Group consisting of AMD subjects without neovascularization prior to initiation of IVA for GA. Study and Control Group subjects had a baseline visual acuity of ≥ 20/200, a total GA lesion area of ≥ 1 mm 2 and ≤ 17.5 mm 2 , and follow-up of 12-months following IVA commencement. Results: A total of 64 patients were analyzed. No significant differences in baseline characteristics were found between cohorts. The Study Group had a greater decrease in visual acuity [− 0.2 (− 0.24 to − 0.16) logMAR versus − 0.04 (− 0.06 to 0.02) logMAR; p< 0.0001], a greater increase in GA lesion growth [1.36 (1.09– 1.63) mm 2 versus 0.52 (0.34– 0.70) mm 2 ; p< 0.0001], and a higher incidence of exudation (p=0.0002) compared to the Control Group during the study period. Conclusion: This study suggests that patients undergoing IVA therapy for GA with pre-existing neovascular AMD have worse visual and anatomic outcomes at 12-months compared to a matched control group without pre-existing neovascularization; such patients therefore should be carefully counseled prior to initiation of IVA for the management of GA.
No takes yet. Share an insight, caveat, or question.
Rush et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: